Monday, December 23, 2024
HomeTagsAJ1-10502

AJ1-10502

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Type II JAK2 Inhibitor

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel, selective small molecules for myeloproliferative neoplasms (MPNs), announced the...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics